Episoder
-
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed. They explore:
The significant interest in diagnostics for the advancement of cancer care.The Joint Commissionâs collaboration with the Coalition for Health AI to establish guidelines for the responsible use of artificial intelligence. The growing understanding that platforms offer an opportunity to expand access and make knowledge more accessible as platform-driven solutions become a reality.The role of laboratorians in guiding the ethical and effective use of data and emerging technologies â and what this means for educating future healthcare professionals.The critical importance of values and ethics in deploying new tools. -
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.
(00:32)
Can you tell us a little bit about yourself and your background?(01:33)
Could you give us a brief overview of this assay?(02:47)
Which patients should have this testing, and when should it be performed?(03:48)
How would the results be used in patient care? -
Manglende episoder?
-
John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test detects antihypertensive medications in urine, providing evidence of whether patients are absorbing their medications or whether a new treatment approach might be needed.
Speaker 3: (00:33)
Could you tell us a little about yourselves and your backgrounds?Speaker 3: (01:41)
Dr. Taler, could you provide us with a brief background on resistant hypertension?Speaker 3: (03:43)
Can you provide a little bit more background on patients who aren't taking their medications?Speaker 3: (05:11)
How do physicians currently assess whether patients are taking their medications?Speaker 3: (07:03)
Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension?Speaker 3: (09:43)
Dr. Taler, can you tell us how doctors can use this new testing to manage their patients? -
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S., a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy. Their discussion covers:
The high prevalence of peripheral neuropathy and why early diagnosis is important. The complexities involved in diagnosing the condition.Symptoms that should prompt clinicians to order advanced testing early in the diagnostic process.How algorithms are enhancing the use of testing to complement other diagnostic tools.Ongoing discovery related to specific antibodies associated with neuropathies.Learn more in our e-book, "Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach."
-
Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.
(01:14)
Could you give us a brief overview of this assay?(02:06)
Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method?(04:00)
When is this test typically ordered for transplant patients? Is it used throughout their treatment?(06:56)
Could an immunocompromised person be unknowingly infected?
(07:31)
Is our quantitative method approved for pediatric patients?
(08:00)
How are the test results used to treat patients?
(10:36)What other infections might providers consider alongside adeovirus?
-
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss global trends in diagnostic manufacturing and their implications for laboratory professionals. Topics include:
Emerging innovations in mass spectrometry, next-generation sequencing, automation, and artificial intelligence. Fierce competition in the global manufacturing landscape as new companies enter the market. Geopolitical dynamics influencing where innovations are deployed. Why laboratory professionals need to drive innovation implementation to maximize benefits for clinicians and their patients. -
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the value laboratories deliver for their entire health system. They cover how laboratories impact:
Growth in revenueGrowth in lab chargesGrowth in ancillary servicesHospital length of stayControl over expensesYou can also find more in-depth information on this topic in âMaximizing your health systemâs financial performance,â a white paper with data-driven ways laboratories support their organizations.
-
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss tick-borne diseases. They cover:
Different diseases patients can get from ticks. Disease prevention, including Dr. Prittâs A through Z flash cards with tips for people to protect themselves from infectious insects.Laboratory medicineâs valuable role in testing and educating providers to diagnose patients quickly and accurately.Clinical areas most likely to encounter patients with tick-borne diseases.Reliable sources for details about the prevalence of different diseases around the country (e.g., U.S. Centers for Disease Control and Prevention (CDC) and Mayo Clinic Laboratories). -
In this episode of âAnswers From the Lab,â William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplifyâąâαSYN (CSF) test. They covered:
Details about how the cerebrospinal fluid biomarker test (Mayo ID: ASYNC) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.Information physicians receive from the test, and when they should consider ordering it for their patients. Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplifyâαSYN. -
Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.
(00:33)
Do you mind telling us a little bit about yourself and your background?(01:45)
Could you please provide us with an overview of arsenic, how people get exposed, and the laboratory testing for arsenic and arsenic speciation?(05:25)
Which patients should have this testing, and when should it be performed?(06:57)
What alternative test options are available, and how does testing at Mayo Clinic compare?(08:37)
How are the results used in patient care?
-
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administrationâs (FDA) oversight of lab-developed tests (LDT). They covered:
Details about the ruling to vacate the FDAâs rule on LDT oversight. What LDT oversight might look like in the future. How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation.
-
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.
(00:32)
Could you provide us a with little bit about your background and yourself?(03:45)
Will you please provide a brief overview of Mayo test 3A5Q?(06:56)
Which patients should have this testing, and when should it be performed?(08:15)
What alternative or complementary tests should be considered?(09:25)
How are the results used in patient care?
(10:38)
Will you help the audience understand the significance of monitoring tacrolimus levels for transplant rejection?
(12:53)
What alleles are included in this test?
-
In this episode of âAnswers From the Lab,â William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
During their conversation, Dr. Morice and Dr. Tan explore:
Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARKÂź from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements. -
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the evolution of retail health. They cover several key topics, including:
The emergence of retail health locations.Three types of care that are well-suited for a retail approach to healthcare.The importance of incorporating diagnostics when designing retail health.Keep up with the latest diagnostic news and Dr. Morice's insights on LinkedIn and X.
-
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss infectious disease activity around the nation. They cover:
The high prevalence of influenza A, avian influenza, measles, and COVID-19. Reliable resources for information on the spread of infectious diseases. Prevention measures and their impact on the spread of infectious diseases. The risks associated with multiple infectious diseases circulating simultaneously at high rates. -
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, for a conversation about innovation in testing for sexually transmitted infections (STI). Topics include:
The advantages and challenges of new types of specimen collection and testing methods, including over-the-counter, at-home, and point-of-care options. Implications home testing has for clinicians and public health. Barriers to making more at-home collection and over-the-counter testing products for STI testing.The growing need for tests to detect resistance markers as antimicrobial resistance increases. -
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, for a conversation about quality management. Specifically, they discuss:
The benefit of investing in quality management for patients, staff, and the organization.How Mayo Clinicâs Department of Laboratory Medicine and Pathology in Rochester evolved and grew its quality management program.The advantage of holding 5â10-minute huddles each day.How the lab leverages education on quality tools and Gemba Walks to empower all staff to invest in quality management. -
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories.
They discuss recent business trends in diagnostics and why it is important for pathologists to stay informed about these trends. Their conversation covers:
Whatâs driving a renewed interest in investing in diagnostics.Why the knowledge pathologists have is so valuable in the current landscape.How the evolving expectations of laboratory professionals will make it important to stay informed about business trends. -
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.
(00:32)
Would you mind telling us a little bit about yourself and your background?(01:58)
Would you give us an overview of membranous nephropathy?(07:14)
Could you tell us a little bit about this new assay?(14:29)
Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?
-
In this episode of âAnswers From the Lab,â host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories.
They discuss Dr. Moriceâs recent article in Beckerâs Hospital Review, âNine Developments Predicted to Shape Laboratory Medicine and Diagnostics in 2025,â and go deeper into conversation about:
The rapid evolution of artificial intelligence and large language models.Digital pathology.Proteomics, metabolomics, and mass spectrometry. - Vis mere
